New Clinical Technology Every NP Should Know About in 2025

New Clinician Resources · 10 min read · April 28, 2025

Clinical technology is advancing faster than most clinicians can track. The challenge is not finding new technology — it is distinguishing between tools that genuinely improve patient care and clinical efficiency, and tools that are expensive, disruptive, and ultimately abandoned. Here is a curated overview of the technologies that are actually changing NP practice in 2025.

Ambient AI Documentation

Ambient documentation assistants — AI systems that listen to patient encounters and generate structured clinical notes — are the most transformative technology to enter primary care in a decade. Tools like Nuance DAX Copilot, Suki, Nabla Copilot, and Abridge are now integrated into major EHR platforms including Epic, Cerner, and Athenahealth.

The clinical impact is significant: providers using ambient documentation report saving 1–2 hours per day on documentation, spending more time in eye contact with patients, and experiencing reduced burnout. The notes generated are generally high quality for routine encounters, though complex or atypical presentations require careful review.

The liability consideration: you are signing the note. Review every AI-generated note before signing. The AI does not carry malpractice liability — you do.

Continuous Glucose Monitoring (CGM)

CGM has moved from a niche tool for type 1 diabetes management to a mainstream technology for type 2 diabetes, prediabetes, and even metabolic health optimization in non-diabetic patients. The Dexterity G7 and Abbott Libre 3 are now covered by Medicare for all patients on insulin and for many patients on non-insulin diabetes medications.

For NPs managing diabetes, CGM data provides a level of insight into glucose patterns that finger-stick testing cannot match. Time-in-range (TIR) — the percentage of time glucose is between 70–180 mg/dL — is now a primary management target alongside HbA1c. Understanding how to interpret ambulatory glucose profiles (AGP) and use them to guide medication adjustments is an essential competency for primary care NPs.

Remote Patient Monitoring (RPM)

RPM platforms allow NPs to monitor patients' vital signs, glucose, weight, and other parameters between visits using connected devices. Patients transmit data from home; the practice receives alerts when values are out of range and bills for the time spent reviewing and acting on that data (CPT codes 99453, 99454, 99457, 99458).

RPM is particularly valuable for managing hypertension, heart failure, COPD, and diabetes. A patient with poorly controlled hypertension who transmits daily blood pressure readings allows their NP to identify patterns, adjust medications, and intervene before a crisis — rather than waiting for the next scheduled visit.

The business case is also compelling: RPM generates significant additional revenue per patient per month (typically $50–$150/month in reimbursement) with relatively low provider time investment.

AI-Assisted Diagnostic Imaging

FDA-cleared AI algorithms are now available for:

Chest X-ray analysis: Detecting pneumothorax, consolidation, effusion, cardiomegaly (Viz.ai, Aidoc)
ECG interpretation: Detecting atrial fibrillation, ST changes, LVH (Eko AI, AliveCor KardiaMobile)
Dermatology: Melanoma and skin cancer detection (DermAI, SkinVision)
Diabetic retinopathy screening: FDA-cleared autonomous AI diagnosis (IDx-DR)
Fundus photography: Optic nerve and retinal assessment

These tools are designed to assist clinical decision-making, not replace it. They flag findings for human review and are most valuable in settings where specialist access is limited — a primary care NP using AI-assisted fundus photography can screen for diabetic retinopathy without waiting for an ophthalmology referral.

Digital Therapeutics (DTx)

Digital therapeutics are software-based interventions that deliver evidence-based therapeutic content to patients via smartphone apps. FDA-cleared DTx products now exist for:

Insomnia: Somryst (CBT-I for chronic insomnia)
Substance use disorders: reSET (for substance use disorder treatment)
Diabetes prevention: Omada, Noom (CDC-recognized DPP programs)
Hypertension: Various RPM-integrated platforms

For NPs, DTx represents an opportunity to extend the therapeutic relationship between visits and deliver evidence-based behavioral interventions at scale. Many DTx products are now covered by commercial insurance and Medicare Advantage plans.

Wearables and Consumer Health Technology

Consumer wearables — Apple Watch, Fitbit, Garmin, Oura Ring — are generating clinical-grade data that patients are increasingly bringing to their providers. The Apple Watch Series 9 can detect atrial fibrillation with FDA clearance, measure blood oxygen saturation, and generate ECG tracings. The Oura Ring tracks sleep stages, heart rate variability, and body temperature.

NPs need to know how to interpret this data — and how to counsel patients about its limitations. A single AFib alert on an Apple Watch is not a diagnosis; it is an indication for a 12-lead ECG and clinical evaluation. A low HRV on an Oura Ring is not a medical emergency; it is a signal worth discussing in the context of the patient's overall health.

The Principle of Thoughtful Adoption

Not every new technology deserves adoption. The questions to ask before integrating a new tool into your practice are: Does it improve patient outcomes? Does it improve clinical efficiency? Does it add liability risk? Does it create data that I know how to interpret and act on? Is the cost justified by the benefit?

The best NPs are neither early adopters who chase every new tool nor late adopters who resist change. They are thoughtful evaluators who adopt technology when the evidence supports it and the workflow integration is sound.